• Users Online: 201
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2018  |  Volume : 7  |  Issue : 3  |  Page : 144-147

Could Biglycan be a biomarker of coronary artery disease? A pilot human study


1 Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Research and Education, Razavi Hospital, Mashhad, Iran
3 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad; Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Al Zahra, Karbala, Iran
4 Department of Anatomy; Department of Cardiology, Birjand Cardiovascular Disease Research Center, Birjand University of Medical Sciences, Birjand, Iran
5 Department of Clinical Pharmacy, School of Pharmacy; Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence Address:
Dr. Amir Hooshang Mohammadpour
P. O. Box 91775-1365, Mashhad
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/rcm.rcm_23_18

Get Permissions

Background: Coronary artery calcification (CAC) is utilized as an important tool for the global risk assessment of cardiovascular events in individuals with intermediate risk. Biglycan (BGN) is a small leucine-rich proteoglycan that induces the calcification of arterial smooth muscle cell. This study aimed to evaluate the correlation between BGN serum concentration and CAC in human for the first time. Patients and Methods: Eighty-four patients with coronary artery disease (CAD) were included in the study. A questionnaire consisting of demographic data and traditional cardiovascular risk factors was completed for all patients. patients did not complete the questionnaire, it was completed by the pharmacy student. CAC score and BGN serum concentrations were determined using computed tomography angiography and enzyme-linked immunosorbent assay method, respectively. Results: There was no significant correlation between BGN serum concentration and total CAC score and also CAC of different branches of coronary artery (P > 0.05). Conclusion: On the basis of our results, BGN serum concentration is not a suitable biomarker of CAD. Studies with a higher sample size are necessary for its confirmation.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed214    
    Printed6    
    Emailed0    
    PDF Downloaded33    
    Comments [Add]    

Recommend this journal